Retail News CRM

Tag: healthcare

  • Manulife Singapore Pioneers Multi-Cancer Screening for Insured, Spearheading Preventive Healthcare Revolution

    Manulife Singapore Pioneers Multi-Cancer Screening for Insured, Spearheading Preventive Healthcare Revolution

    Manulife Singapore is intensifying its commitment to preventative healthcare and lifespan enhancement solutions via a new partnership with Guardant Health, a precision oncology expert. This strategy makes Manulife the pioneer insurance firm in Singapore to provide the Shield™ multi-cancer detection (MCD) blood test, available to eligible customers from May 2026.

    This collaboration is part of a broader Asian alliance between the two companies, covering Singapore, Hong Kong, and the Philippines. The partnership reiterates Manulife’s overarching strategy of amalgamating health protection with long-term wealth and lifespan planning.

    Emphasizing Proactive Detection

    Designed to screen ten prevalent cancers with a single blood draw, the Shield™ MCD lab-crafted test underscores several cancers with high fatality rates in Singapore. The test was recently awarded the “Oncology Product Innovation of the Year” title at the Healthcare Asia Medtech Awards and received the Breakthrough Device Designation by the US Food and Drug Administration (FDA).

    This partnership advances the pre-existing relationship between Manulife and Guardant Health, as the latter already offers the Guardant360® Liquid test for advanced solid tumours to customers in Singapore.

    Longevity as a Focal Point

    The partnership evidences an increasing emphasis on preventative care and healthy ageing among insurers as Asia’s populace demographic shift. “As longevity increases, the primary concern is the quality of those extended years,” stated Benoit Meslet, President and CEO of Manulife Singapore. “Providing customers with early insights into their health enables them to make informed decisions today for a healthier tomorrow.”

    Singapore is one of the fastest-ageing societies in Asia, with healthcare systems prioritising preventative and personalised care. In 2024, cancer was the predominant cause of death in Singapore, accounting for over a quarter of all fatalities.

    Manulife’s initiative aligns with the findings from the 2025 Asia Care Survey, showing that over half of Singapore consumers perceive cancer as the hardest illness to prevent.

    Questions & Answers

    What is the new collaboration between Manulife Singapore and Guardant Health about?

    The collaboration aims to offer the Shield™ multi-cancer detection (MCD) blood test to eligible Manulife customers in Singapore, aiding in the early detection of ten common cancers.

    How does this partnership align with Manulife’s broader strategy?

    This partnership coincides with Manulife’s broader strategy of blending health protection with long-term wealth and lifespan planning. It underscores the insurer’s emphasis on preventative care and healthy ageing.

    What insights does the 2025 Asia Care Survey provide?

    The survey reveals that over half of Singapore consumers consider cancer as the most difficult disease to prevent, indicating the importance of early detection and preventative healthcare.

  • Citi Strengthens Healthcare Investment Banking with Former Goldman Sachs Executive in Australasia

    Citi Strengthens Healthcare Investment Banking with Former Goldman Sachs Executive in Australasia

    Ben Bartholomaeus, a former executive at Goldman Sachs, has been appointed by Citi as the Head of Healthcare for Australia and New Zealand within their Capital Markets and Advisory team. This key role will see Bartholomaeus drawing upon Citi’s global reach, industry knowledge, and execution proficiency to the benefit of its healthcare clientele in the Australasian region.

    Base of Operations

    Bartholomaeus will operate out of Sydney and report to Philippe Perzi and Ben Connolly, the co-heads of Capital Markets and Advisory for Australia and New Zealand. Additionally, he will report to Ling Zhang, the Head of Healthcare for the Asia Pacific region.

    Prior to this appointment, Bartholomaeus held the position of Head of Healthcare in the Corporate Advisory Division for Australia and New Zealand at Goldman Sachs.

    A Market Leader

    Citi has an established reputation as a leading force in healthcare investment banking. It has retained its top position as a global advisor for mergers and acquisitions within the healthcare sector from 2024 through 2026 year-to-date. During this period, Citi has led major transactions for clients in various healthcare sectors including biopharma, medtech, and life science tools and diagnostics.

    Questions & Answers

    Who has Citi appointed as the new Head of Healthcare for Australia and New Zealand?
    – Citi appointed Ben Bartholomaeus, a former Goldman Sachs executive, as the Head of Healthcare for Australia and New Zealand.

    What role will Bartholomaeus be playing at Citi?
    – Bartholomaeus will be responsible for bringing Citi’s global connectivity, sector insights, and execution expertise to healthcare clients in the Australasian region.

    What is Citi’s standing in healthcare investment banking?
    – Citi is a leader in healthcare investment banking. It has consistently secured the top rank as a global advisor for mergers and acquisitions in the healthcare sector from 2024 through 2026 year-to-date.

  • 2026 Health Sector Boom: Five Key Drivers Powering a Robust Year in Healthcare

    2026 Health Sector Boom: Five Key Drivers Powering a Robust Year in Healthcare

    The healthcare industry is entering the new year with a strong momentum, backed by increased transparency surrounding government healthcare policies and a surge of investor interest. The sector’s future earnings prospects are on the rise, spurred by a robust innovation pipeline and the emergence of new market segments. Despite this, healthcare stocks continue to trade at a discount relative to the global market, creating a re-evaluation underway that is accelerating. At present levels, there are still appealing opportunities for increasing exposure to the healthcare sector.

    Five Key Developments Driving the Sector’s Momentum

    The sector’s momentum is being bolstered by five key developments:

    Firstly, policy clarity is attracting investors back to the sector. The pricing agreement reached between the US administration and Pfizer in September, and subsequent agreements with Eli Lilly and Novo Nordisk in November, marked a significant turning point. These developments have resulted in a predictable framework for drug pricing and reimbursement policies, thereby reducing uncertainty and improving planning visibility. Reaction from investors was swift, with healthcare emerging as one of the strongest global stock market performers this quarter, attracting an additional $8 billion in capital to healthcare ETFs worldwide in just three months.

    Secondly, a re-evaluation process has begun, with further potential for catch-up. Healthcare valuations are moving back towards historical averages, but the sector is still valued approximately 13% lower than global stocks. The future looks bright for healthcare companies, with average profit growth predictions for biopharmaceuticals and life science tools between 2024 and 2027 standing at approximately 15%, more than double the historical growth rate of about 7% per year.

    Thirdly, the biopharma sector is set to benefit from formidable growth drivers and high M&A capacity. Looking ahead to 2026, this sector stands to gain from various structural trends such as new oncology treatment classifications, advances in obesity and diabetes treatments, and therapeutic innovations in cardiovascular care.

    Fourthly, the medical technology sector continues to be a key growth driver, spurred by high demand in established markets and the emergence of new billion-dollar niches. Markets such as robot-assisted surgical systems, glucose monitoring devices, and structural heart disease treatment continue to register double-digit growth rates.

    Lastly, emerging markets are boosting their innovation capabilities and market clout. These markets are steadily transforming into innovation powerhouses in their own right. China, for instance, is transitioning from an out-licensing partner to a global pharmaceutical player, while India’s rapidly growing middle class and substantial government healthcare infrastructure spending stand out as growth engines.

    Conclusion

    Entering 2026, the healthcare sector is backed by strong structural growth drivers and improved earnings visibility. Innovation continues to be key, supported by robust pipelines, new therapy platforms, and tech-enhanced solutions. However, the sector’s performance disparity, as measured by the MSCI World Healthcare Index, is also noteworthy, with a performance gap of +72% and -38% between the best and worst-performing stocks in the first half of 2025.

    After a recent period of policy uncertainty, the healthcare sector is back in its historical position of innovation, growth, and high operational visibility, a position from which it has consistently delivered tangible value.

    Questions & Answers

    What has attracted investors back to the healthcare sector?
    Investors are being drawn back to the healthcare sector due to increased policy clarity, including agreements on drug pricing and reimbursement policies between the US administration and pharmaceutical companies.

    What are some key growth drivers for the biopharma sector looking ahead to 2026?
    Key growth drivers for the biopharma sector include new classifications of oncology treatments, advancements in obesity and diabetes treatments, and therapeutic innovations in cardiovascular care.

    How are emerging markets contributing to the growth of the healthcare sector?
    Emerging markets like China and India are increasingly becoming innovation powerhouses in their own right. China is transitioning from an out-licensing partner to a global pharmaceutical player, while India’s growing middle class and substantial government spending on healthcare infrastructure are key growth drivers.

  • Revolutionizing Workplace Wellness: CelcomDigi Debuts 5G-Enhanced MediHub for Comprehensive Employee Healthcare

    Revolutionizing Workplace Wellness: CelcomDigi Debuts 5G-Enhanced MediHub for Comprehensive Employee Healthcare

    CelcomDigi Berhad, a leading telecommunications company, has launched MediHub, a state-of-the-art healthcare facility utilizing 5G technology. The aim of this facility is to provide its employees with readily available professional healthcare services within their work environment.

    The MediHub: A Comprehensive Healthcare Solution

    MediHub, located within the CelcomDigi compound, is a comprehensive health solution offering both physical and mental health services. It functions as an accessible platform for employees to engage in virtual consultations with licensed healthcare professionals, including medical practitioners, psychiatrists, and psychologists. The primary objective of MediHub is not just to treat illnesses, but also to create a safe and supportive atmosphere for employees to thrive professionally.

    Specialized Areas within MediHub

    The facility comprises two main areas: the Care Room and the Mind Room. The former is a virtual clinic that allows employees to consult with licensed medical practitioners via MediDoc, a secure telehealth platform. As such, employees can receive medical advice, diagnoses, and prescriptions without leaving their workplace. Alongside this, the MediKiosk, a smart health station, performs quick vital checks and provides instant health reports to ensure accurate, real-time data forms the basis of each consultation.

    The Mind Room, on the other hand, focuses on mental wellness. It provides a private space for employees to receive counselling and emotional support from licensed psychiatrists and psychologists. This room also houses stress management sessions and a relaxation area. Moreover, the Mind Room offers self-assessment tools like DASS-21 (Depression, Anxiety, and Stress Scale-21) to help employees understand their emotional health and proactively work towards mental resilience.

    CelcomDigi’s Commitment to Employee Wellbeing

    T. Kugan, Chief Innovation Officer of CelcomDigi, emphasized the company’s dedication to utilizing technology for improving everyday healthcare for its employees. He highlighted how the integration of 5G connectivity with AI-driven solutions from CelcomDigi’s AI Experience Centre (AiX) can deliver accessible healthcare facilities. He further noted that these innovations are contributing to the betterment of Malaysian enterprises and the nation, as well as supporting the holistic wellbeing of their organization.

    CelcomDigi is deeply committed to the wellbeing of its employees and exemplifies this by consistently promoting an inclusive, high-performing work environment. In 2024, it became the first Malaysian organization to achieve ISO 45003:2021 certification, underlining its commitment to a resilient, people-centric culture.

    AiX Innovations in Healthcare

    MediHub represents the application of CelcomDigi’s AiX innovations, combining 5G connectivity and AI to deliver scalable and convenient healthcare solutions. With the support of over 56 local and international ecosystem partners, AiX integrates more than 61 solutions across eight verticals, with 28 use cases already in place. This initiative demonstrates the practical applications of digital healthcare in providing real-time connectivity, AI-driven insights, and a seamless experience.

    Questions & Answers

    What is the purpose of the MediHub?
    The MediHub is designed to provide accessible professional healthcare services to CelcomDigi’s employees within their workplace. It focuses not only on treating illnesses but also fostering a supportive environment for professional growth.

    What services does the MediHub offer?
    The MediHub offers both physical and mental health services. It enables virtual consultations with medical practitioners, psychiatrists, and psychologists. The hub also provides stress management sessions, a relaxation area, and self-assessment tools for mental health.

    How does CelcomDigi use technology to enhance healthcare?
    CelcomDigi utilizes 5G connectivity and AI-driven solutions to provide scalable and convenient healthcare services. The company’s AI Experience Centre (AiX) integrates these technologies to deliver real-time connectivity and insights, demonstrating the practical applications of digital healthcare.

  • H3Tech Leverages Vietnam’s Tech Prowess to Transform Global Healthcare Landscape

    H3Tech Leverages Vietnam’s Tech Prowess to Transform Global Healthcare Landscape

    H3Tech, a pioneer in healthcare technology, seeks to revolutionize the U.S. healthcare sector by employing a sophisticated tech approach and a business model rooted in Vietnam. The company differentiates itself from other offshore providers by being a strategic development collaborator for healthcare tech businesses both within the U.S. and worldwide.

    According to Mikael Ohman and Michael Gilbert, the co-CEOs and co-founders, the healthcare sector represents close to 20% of the U.S. economy. However, it is plagued by high costs and mediocre outcomes. Observing the potential of technology to not only cut costs but also enhance quality, they brought H3Tech into existence. Their vision was to utilize high-tech solutions to make a significant impact on the lives of individuals involved in healthcare.

    Both Mikael and Mike possess extensive experience working with international software engineering firms across the globe. They note that Vietnam boasts some of the highest quality software engineers and technology leaders globally. Thus, when it came to launching H3Tech, Vietnam was their preferred choice. Mike recognized and acknowledged the efforts the Vietnamese government has put into education and additional support for the technology sector.

    Questions & Answers

    What is the goal of H3Tech?
    H3Tech aims to revolutionize the U.S. healthcare sector by leveraging advanced technology and a business model rooted in Vietnam.

    How does H3Tech differentiate itself from other offshore vendors?
    Unlike typical offshore vendors, H3Tech positions itself as a strategic development collaborator for healthcare tech businesses, both within the U.S. and worldwide.

    Why was Vietnam chosen as the primary location for H3Tech’s operations?
    Vietnam was chosen due to its high-quality software engineers and technology leaders. The Vietnamese government’s investment in education and additional support for the technology sector was also a significant factor in the decision.

  • Pharma Leaders At Flypharma Highlight Air Cargo’s Role In Global Health

    Pharma Leaders At Flypharma Highlight Air Cargo’s Role In Global Health

    At the FlyPharma Amsterdam 2025 conference, leaders from the worldwide pharmaceutical industry gathered to highlight the importance of collaboration for the steady global transportation of essential healthcare items and life-saving medicines. The conference took place amidst the backdrop of rapidly changing regulations, shifting trade flows, and an uncertain geopolitical landscape.

    Growth in Pharma Sector Increases Demand for Specialised Air Cargo

    The global healthcare and pharmaceutical industry is projected to achieve a total worth of USD 1.77 trillion by 2025. This growth is primarily attributed to advances in biologics, digital health, and personalized medicine, along with increased patient access on a global scale.

    The industry’s momentum is directly reflected in increased demand for airfreight capacity, especially for temperature-sensitive, high-value shipments. The pharma airfreight segment alone is predicted to witness over 6 percent annual growth, as manufacturers and logistics providers prioritize speed, dependability, and adherence to Good Distribution Practice (GDP) standards.

    Air cargo carriers and airports are making significant investments in IoT tracking, cold-chain infrastructure, and digital visibility tools to cater to this growing vertical. The fastest growth is anticipated in corridors linking Asia, Europe, and North America. The pharma and healthcare logistics sector is emerging as a strong and premium segment within the global air cargo market.

    Schiphol: A Global Centre for Pharma Logistics

    Amsterdam Airport Schiphol is a crucial global hub for pharmaceutical logistics. With its central European location, advanced infrastructure, and robust network of logistics partners, the airport is essential for global pharmaceutical supply chains. Schiphol contributes significantly to the worldwide distribution of vaccines and medicines and enhances the Dutch economy, further establishing the Netherlands as a hub for international trade and innovation in life sciences.

    The pharmaceutical logistics ecosystem at Schiphol has considerable implications not only for global public health but also for the Dutch economy. In 2024, the Netherlands exported pharmaceutical products worth USD 38.49 billion, highlighting the sector’s role in driving trade, innovation, and high-value employment. Schiphol’s success as a pharma logistics hub encourages companies to invest, expand, and drive innovation in the Netherlands, making the country more competitive and appealing to life sciences entities.

    Schiphol’s importance as a global logistics hub was further underscored during the COVID-19 pandemic, during which it served as one of Europe’s primary gateways for vaccine transportation and temperature-sensitive pharmaceuticals.

    The Role of Air France KLM Martinair Cargo in Pharma Logistics

    Air France-KLM Martinair Cargo (AFKLMP Cargo) has positioned itself as a leading player and innovator in pharmaceutical logistics, being among the first airlines to receive IATA CEIV Pharma certification. The airline’s dual-hub structure in Amsterdam Schiphol and Paris Charles de Gaulle, situated in Europe’s “pharma belt,” provides unique resilience and adaptability in a fluctuating market.

    According to GertJan Roelands, SVP Commercial, AFKLMP Cargo, the company’s growth in the pharmaceutical and healthcare segment has been a strategic priority over the past five years. The airline has made considerable investments in infrastructure and introduced new digital solutions while optimizing processes to enhance resilience and transport quality. The airline’s commitment to this strategy is reflected in its record-breaking performance in the pharmaceutical and healthcare segment and its increasing market share.

    Innovation, Sustainability, and Excellence in Cool Chain

    AFKLMP Cargo continues to expand cool-room capacity, develop digital monitoring dashboards for operational visibility, and pioneer sustainable temperature-control solutions such as CO₂-based refrigerant technology at Paris CDG. As personalized medicine and advanced therapies gain traction, the airline collaborates closely with shippers, forwarders, and life science clusters, providing time-critical solutions that are fully compliant with GDP and CEIV.

    Despite market volatility and geopolitical pressures, AFKLMP Cargo remains steadfast in its focus on on-time delivery and maintaining the integrity of the cool chain supply. The resilience demonstrated during the pandemic continues to shape the airline’s long-term strategy.

    In the words of GertJan Roelands, “Pharmaceutical logistics is not just about transportation — it’s about trust, responsibility, and resilience. Our mission is to deliver healthcare products safely and reliably, adapting to new challenges while ensuring patients around the world receive the medicines they need.”

    Questions & Answers

    What are the main factors driving the growth of the global pharmaceutical industry?
    The main factors driving this growth include advances in biologics, digital health, and personalized medicine, along with increased patient access globally.

    What is the projected growth for the pharma airfreight segment?
    The pharma airfreight segment is predicted to grow more than 6 percent annually.

    What role has Schiphol played in global pharmaceutical logistics?
    Schiphol serves as a crucial global hub for pharmaceutical logistics, contributing significantly to the worldwide distribution of vaccines and medicines, and enhancing the Dutch economy.

  • Sigma Healthcare Resets Merger Synergy Target With Chemist Warehouse Amidst Significant Revenue Surge

    Sigma Healthcare Resets Merger Synergy Target With Chemist Warehouse Amidst Significant Revenue Surge

    Sigma Healthcare has revised its merger synergy target with Chemist Warehouse, following a significant increase in both its top and bottom line results last year.

    New Merger Synergy Targets

    Sigma Healthcare has now set its synergy target for the merger at $100 million per annum, a substantial increase from the previous target of $60 million. The company aims to attain this goal within a span of four years.

    The last fiscal year ending June 30 saw an 82.2 per cent surge in revenue to $6 billion. Chemist Warehouse reported a 14 per cent increase in retail network sales, and a notable 11.3 per cent rise in like-for-like sales across the Australian network.

    Brand Expansion and Financial Performance

    Over the past year, Sigma increased its portfolio of proprietary and exclusive brand products, with a notable release of 269 products in the Wagner generics range last November. The sales of proprietary and exclusive label products saw an increase of over 20 per cent.

    When it comes to the bottom line, statutory earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 33.6 per cent to $824 million, while the net profit after tax (NPAT) reported a slight decline of 2.1 per cent to $530 million. However, normalized EBITDA saw a rise of 41.4 per cent to $884 million, and NPAT also increased by 40.1 per cent to $579 million.

    By June 30, the net debt stood at $752 million, significantly lower than the initial net debt range of $1 billion to $1.3 billion as indicated in the merger prospectus.

    Anticipated Growth and Future Plans

    Sigma CEO and MD, Vikesh Ramsunder, stated that the merger with Chemist Warehouse has resulted in a more robust, integrated healthcare business with enhanced scale, capability, and market reach. He emphasized that the FY25 results highlight the group’s momentum and potential for sustained growth.

    As part of its plan for the new fiscal year, Sigma intends to continue the expansion of Chemist Warehouse stores both domestically and internationally at a steady pace. It also plans to introduce new proprietary and exclusive label products to enhance margins.

    Sigma also announced the closure of distribution centres in South Guildford, WA, and Port Adelaide, SA, with services being moved to existing centres in Canning Vale and Pooraka. The company also plans to gradually close brick-and-mortar Chemist Warehouse stores in China over the next few years, focusing on achieving profitable growth, with the Chinese market being serviced through online channels thereafter.

    Questions & Answers

    What is the new merger synergy target set by Sigma Healthcare?
    The new merger synergy target set by Sigma Healthcare is $100 million per annum, up from the previous target of $60 million.

    What are Sigma Healthcare’s plans for the new fiscal year?
    Sigma plans to expand Chemist Warehouse stores in Australia and internationally, launch new proprietary and exclusive label products, and shift services from closing distribution centres to existing ones.

    What is Sigma Healthcare’s strategy for the Chinese market?
    Sigma Healthcare plans to gradually close Chemist Warehouse physical stores in China over the next few years, focusing on servicing the Chinese market through online channels.

  • Anindya Dasgupta Appointed New Asia-pacific President For Kenvue: A Strategic Move For Johnson & Johnson

    Anindya Dasgupta Appointed New Asia-pacific President For Kenvue: A Strategic Move For Johnson & Johnson

    Leadership Transition at Kenvue

    Kenvue, Johnson & Johnson’s consumer healthcare sector, has appointed Anindya (Andy) Dasgupta as the new group president for the Asia-Pacific region. The appointment is effective as of July 14th.

    Mr. Dasgupta will be succeeding Ellie Xie, who will remain for a short period to ensure a smooth transition of leadership.

    A Wealth of Experience

    Dasgupta’s near thirty-year career in global consumer goods equips him with a plethora of knowledge and skills for his new role. His background includes senior positions at prominent companies such as GSK, PepsiCo, Fonterra, and Imperial Brands.

    Kenvue CEO, Thibaut Mongon, praised Dasgupta as a transformational commercial business leader. He commended Dasgupta’s proven skills in commercial strategy, sales, marketing, and business development. Mongon expressed his excitement about Dasgupta’s addition to the leadership team and anticipates his results-driven leadership approach in the Asia Pacific region.

    Directing Kenvue’s Asia-Pacific Operations

    In his newly assumed position, Dasgupta will manage Kenvue’s fully integrated operations in the Asia-Pacific. His responsibilities will include guiding the company’s regional growth strategy. He will also exploit the rapidly evolving innovation in markets, data, technology, and science to leverage company growth.

    Questions & Answers

    What is Anindya Dasgupta’s new role at Kenvue?
    Anindya Dasgupta has been appointed as the new group president for Asia-Pacific at Kenvue, Johnson & Johnson’s consumer healthcare division.

    What are some of the companies Dasgupta has previously worked for?
    Dasgupta has held senior roles at GSK, PepsiCo, Fonterra, and Imperial Brands.

    What will be Dasgupta’s responsibilities in his new role?
    Dasgupta will be responsible for overseeing Kenvue’s fully integrated Asia-Pacific operations, directing the company’s regional growth strategy, and leveraging innovation in markets, data, technology, and science.

  • 300,000 Seniors in Singapore to Benefit from Nearly US$1,000 Health Support Initiative

    300,000 Seniors in Singapore to Benefit from Nearly US$1,000 Health Support Initiative

    Around 300,000 seniors from Singapore’s “Pioneer Generation” will soon receive government top-ups ranging from SGD 300 to SGD 1,200 (approximately US$234 to US$937) this July, in recognition of their significant contributions during the nation’s early years.

    Generous Increase in Health Support

    This year’s top-up amounts surpass last year’s figures of SGD 250 to SGD 900, as reported by the Ministry of Finance in a statement Monday. The total commitment for this initiative exceeds SGD 160 million, reflecting the government’s dedication to supporting its older citizens.

    These financial top-ups are designed to cover various medical expenses, including premiums for insurance plans, eldercare programs, as well as hospitalization costs and day surgeries. Notably, this financial boost is in addition to the annual vouchers provided to Singaporeans aged 65 and older.

    Supporting Seniors at Every Stage

    To qualify for the top-ups, seniors must be at least 76 years old, with the oldest citizens, aged 91 and above, receiving the highest amount of SGD 1,200. The Pioneer Generation Package, introduced in 2014, serves as a heartfelt tribute to the contributions of these individuals during the country’s formative years.

    The benefits don’t stop there; those aged 91 and above will continue to have their MediShield Life premiums fully covered, while younger pioneers can expect around two-thirds of their premiums to be taken care of.

    In a nation where every dollar counts, the initiative exemplifies how Singapore values its past while investing in the health and well-being of its elders. After all, nothing says “thank you” quite like a little extra cash for your hospital visits!

    Questions & Answers

    Who is eligible for these health support top-ups?
    Eligible seniors for the top-ups are those aged 76 and above, with those 91 years and older receiving the highest benefits.

    How much total funding is allocated for this initiative?
    The total funding for the top-ups is over SGD 160 million, reflecting the government’s commitment to its senior population.

    What does the top-up cover?
    The financial top-up aids in covering insurance premiums, eldercare programs, and various medical expenses, ensuring that seniors maintain access to essential health services.

  • APAC Healthcare Workers Raise Alarm on AI and Data Gaps Impacting Patient Care

    APAC Healthcare Workers Raise Alarm on AI and Data Gaps Impacting Patient Care

    Retail businesses in Asia are in the midst of a transformative phase, as innovative strategies continue to reshape the landscape. With digital integration skyrocketing, brands are reimagining customer engagement and shopping experiences to keep pace with rapidly evolving consumer preferences.

    Digital Trends Transforming Retail

    Retailers across the region are harnessing the power of technology to enhance their offerings. The use of artificial intelligence, augmented reality, and data analytics is not just a trend—it’s a necessity. These technologies are enabling personalized shopping journeys, where consumers receive tailored recommendations, making every interaction feel unique and significant. In essence, the retail experience is swiftly becoming as much about the journey as it is about the destination.

    Experiential Shopping: The New Norm

    Gone are the days when shopping was a simple transaction. Today’s consumers seek immersive experiences that captivate their senses and create lasting memories. Retail outlets are evolving into multifunctional spaces where customers can enjoy everything from gourmet food tastings to interactive product demonstrations. Imagine sipping artisanal coffee while engaging in a lively workshop on sustainable fashion right in the heart of a department store—how delightful is that?

    Omnichannel Strategies on the Rise

    With the rise of e-commerce, retailers are increasingly adopting omnichannel strategies, seamlessly blending in-store and online experiences. Click-and-collect services, live chat support, and virtual shopping assistants are just a few methods being employed to ensure customers can interact with brands in ways that suit them best, whether they’re browsing in their pajamas or navigating a bustling shopping mall.

    As the retail scene evolves, partnering with innovative advertising can further amplify outreach. Agencies are keen on helping businesses craft compelling digital campaigns and engaging them through vivid storytelling.

    Emerging Markets: A Hotbed for Innovation

    Emerging markets in Asia are brimming with potential, sparking exciting retail ventures and attracting global players eager to capitalize on this growth. Brands are not only looking for market entry but are also tailoring products to cater to local tastes and preferences. From street food to fashion, the region offers a rich tapestry of cultural diversity that is influencing product lines and marketing strategies.

    As a surprise twist, a few unconventional retail experiments—like pop-up stores in unexpected locations—are turning heads and attracting curious shoppers, proving that creativity knows no bounds in today’s retail world.

    Questions & Answers

    What are the key factors driving the transformation of retail in Asia?
    The key factors include the integration of technology, the demand for personalized shopping experiences, and the rise of omnichannel strategies that seamlessly connect online and offline interactions.

    How is experiential shopping shaping consumer behavior?
    Experiential shopping is captivating consumers by offering unique, immersive experiences that go beyond traditional transactions, thus fostering stronger emotional connections with brands.

    What role do emerging markets play in the future of retail?
    Emerging markets serve as a hotbed for innovation, drawing international brands that seek to meet diverse local preferences and explore unique retail opportunities that cater to this burgeoning consumer base.

  • China’s AI Surge Drives Digital Health Market Growth

    China’s AI Surge Drives Digital Health Market Growth

    GlobalData’s research indicated that, in 2024, China accounted for approximately 20% of the digital health market in the Asia Pacific (APAC), reflecting the rising demand for innovations like DeepSeek in the healthcare field.

    Pratibha Thammanabhatla, a Medical Devices Analyst at GlobalData, noted, “The recent introduction of Qwen2.5-Max, Kimi k1.5, and DeepSeek demonstrates China’s expanding presence in the AI industry and its commitment to achieving technological independence. The advanced AI capabilities they offer, such as significant efficiency improvements, enhanced reasoning, and accessibility, have the potential to enhance diagnostic capabilities, provide personalized recommendations, and improve communication between patients and healthcare providers.”

    Alibaba Cloud claimed that its latest Qwen2.5-Max has shown significant advantages over other AI models like Llama 3.1 405B, DeepSeek-V3, and Qwen2.5 72B when assessed using benchmark tools such as Arena-Hard, LiveBench, LiveCodeBench, and GPQA Diamond. They anticipate that advancements in post-training techniques will take the next version of Qwen2.5-Max to new heights.

    Thammanabhatla concluded, “While AI has the potential to transform healthcare by enhancing efficiency and patient outcomes, challenges such as data privacy, doctor-patient relationships, and a shortage of adequately trained personnel need to be addressed for successful implementation. A collaborative approach involving stakeholders from different countries and sectors, including healthcare professionals, regulators, and data privacy experts, is crucial to overcoming these challenges and promoting wider adoption.”

    Lees ook:

  • UPS bolsters healthcare logistics capabilities with cold-chain acquisitions

    UPS bolsters healthcare logistics capabilities with cold-chain acquisitions

    UPS announced that it has agreed to acquire Frigo-Trans, and its sister company BPL, (together “Frigo-Trans”) industry-leading, complex healthcare logistics providers based in Germany. Once completed, the acquisition will enhance UPS’s end-to-end capabilities throughout Europe for UPS Healthcare customers who increasingly require temperature-sensitive and time-critical logistics.

    “The fast-paced innovation in the pharmaceutical industry is creating the need to have more integrated cold and frozen supply chains,” said UPS EVP and President of International, Healthcare and Supply Chain Solutions Kate Gutmann. “Frigo-Trans will help deepen our portfolio of solutions for our customers and accelerate our journey to become the number one complex healthcare logistics provider in the world addressing their needs.”

    Frigo-Trans’ network includes temperature-controlled warehousing that covers six temperature zones from cryopreservation (-196°C) to ambient (+15° to +25°C); a Pan-European cold chain transportation solution and temperature-controlled and time-critical freight forwarding capabilities.

    The transaction is expected to close in the first quarter of 2025, subject to customary regulatory reviews and approvals. The value and terms of the transaction are not being disclosed at this time.

    Lees ook:

    Lees ook:

  • UPS to expedite pharma, AOG handling with new acquisition

    UPS to expedite pharma, AOG handling with new acquisition

    UPS has entered into an agreement with private equity firm Quad-C Management to acquire MNX Global Logistics (MNX), a time-critical logistics provider with clients in the aerospace, healthcare and pharma industries.

    UPS will look to leverage MNX’s specialist capabilities in airport on ground (AOG) delivery services and temperature-controlled logistics for its healthcare unit and clinical trial logistics subsidiary Marken.

    The company will also offer industry-leading time-critical, temperature-sensitive logistics services together with UPS Express Critical. The transaction is expected to close by year-end, subject to customary regulatory review and approval. UPS has not declared the value and terms of the transaction at the time of writing.

    Lees ook:

  • ANZ Pharma becomes Fiji Kava’s distributor in New Zealand

    ANZ Pharma becomes Fiji Kava’s distributor in New Zealand

    Fiji Kava (FIJ) has appointed healthcare wholesale company ANZ Pharma as its exclusive distributor in New Zealand.

    As part of the agreement, ANZ Pharma will launch the Fiji Kava range of capsules and drinking kava in the New Zealand market.

    The products will be stocked through retail channels such as supermarkets, tourism retail outlooks and petrol, route and convenience stops.

    The contract includes a sales performance requirement of $1.1 which, if met, could extend the deal by another three years.

    “Alongside the Australian market, the New Zealand market has seen a big increase in demand for kava products over the last year,” Fiji Kava CEO Anthony Noble said.

    “The team has worked hard to find the right partner, and working with a strong company like ANZ Pharma, who have a stable of national and multinational clients including Bondi Sands, Herbs of Gold, Unilever, Red Bull and Reckitt, gives us great confidence to re-enter this important market.”

    ANZ Pharma Director Nitin Patel said the partnership was in alignment with the company’s long-term strategic goal of bringing high-quality products at great value to New Zealand consumers.

  • Novartis sponsors expert talkshow to raise breast cancer awareness

    Novartis sponsors expert talkshow to raise breast cancer awareness

    The talk show “Spread the Belief Program”, organized by HCMC Oncology Hospital with Novartis’s support, has helped the audiences answer basic questions about breast cancer.

    Breast cancer ranks first among the most common cancers in women in the world and Vietnam. According to Global Cancer Statistics 2020, more than 2.2 million people worldwide were diagnosed with breast cancer and about 680,000 people died from this disease in 2020.

    In Vietnam, breast cancer accounts for 25.8% of cancer cases in women with more than 21,555 new cases and 9,345 deaths in 2020.

    If the 5-year survival rate in the very early stage reaches 98%, in the late stage, this rate is only about 10%. More worryingly, breast cancer patients are getting younger.

    Due to psychological reasons, many people at risk – particularly women – tend to delay screening for early detection of breast cancer. The late detection of this disease makes treatment difficult, less efficient, and costly.

    Therefore, regular screening for timely diagnosis and detection is crucial to help patients actively choose treatment methods, increase treatment efficiency, and save costs.

    In order to support the community to update information about the disease, HCMC Oncology Hospital organized the “Breast Cancer Awareness Program” talk show with the sponsorship of Novartis Vietnam.

    This is also part of Novartis’ long-term commitment to ensuring easy access to treatment for patients through public health activities.

    Dr. Phan Thi Hong Duc, Head of the Internal Medicine Department of Breast, Gastroenterology, Liver and Urology, HCMC Oncology Hospital provided useful information about the disease during the talk show.

    The expert guest emphasized the importance and effectiveness and timely screening measures as well as medical advances in the treatment of breast cancer today.

    Although breast cancer is common and dangerous, patients still have the opportunity to treat and prevent the development of this disease.

    The March 2022 report of the American Cancer Society (ACS) found that 99% of those treated for breast cancer at the earliest stage live 5 years or longer after being diagnosed and the survival rate of people with metastatic breast cancer is 28% if treatment is maintained for a long time.

    Today’s medicine has made great strides in breast cancer treatments such as surgery, radiation therapy, and chemotherapy, combined with other treatments such as hormone therapy, biological therapy (targeted therapy), immunotherapy, and so on.

    Lees ook: